Ray Dalio
APLS

Ray Dalio’s Apellis Pharmaceuticals APLS Stock Holding History

Ray Dalio’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
34,913
-108,892
-76% -$2.35M 0.01% 725
2025
Q4 		$3.61M Buy
+143,805
New +$3.37M 0.01% 619

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ray Dalio's APLS Position: Q1 2026 in Review

Ray Dalio reduced its Apellis Pharmaceuticals (APLS) stake by 76% in Q1 2026, selling an estimated $2.35M and leaving 34,913 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #725.

Ray Dalio first reported a position in APLS in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.61M in Q4 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Ray Dalio held 34,913 shares of Apellis Pharmaceuticals worth $1.4M as of Q1 2026.
  • Ray Dalio sold 108,892 Apellis Pharmaceuticals shares in Q1 2026, an estimated $2.35M.
  • Apellis Pharmaceuticals made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #725 holding.
  • Ray Dalio first reported a position in Apellis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Ray Dalio's Apellis Pharmaceuticals position peaked at $3.61M in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.